Japan Cancer Biomarker Market Size & Outlook, 2026-2033
The cancer biomarker market in Japan is expected to reach a projected revenue of US$ 3,383.7 million by 2033. A compound annual growth rate of 12.6% is expected of Japan cancer biomarker market from 2026 to 2033.
- Clinical Diagnostics
- In Vitro Diagnostics
- Cancer Biomarker Market Outlook
- In Vitro Diagnostics
Revenue, 2025 (US$M)
$1,316.9
Estimate, 2026 (US$M)
$1,474.5
Forecast, 2033 (US$M)
$3,383.7
CAGR, 2026 - 2033
12.6%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the cancer biomarker market
Every figure cited from GVR research
Japan cancer biomarker market highlights
- The Japan cancer biomarker market generated a revenue of USD 1,316.9 million in 2025 and is expected to reach USD 3,383.7 million by 2033.
- The Japan market is expected to grow at a CAGR of 12.6% from 2026 to 2033.
- In terms of segment, lung cancer was the largest revenue generating type in 2025.
- Lung Cancer is the most lucrative type segment registering the fastest growth during the forecast period.
Cancer biomarker market data book summary
| Market revenue in 2025 | USD 1,316.9 million |
| Market revenue in 2033 | USD 3,383.7 million |
| Growth rate | 12.6% (CAGR from 2026 to 2033) |
| Largest segment | Lung cancer |
| Fastest growing segment | Lung Cancer |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer |
Other key industry trends
- In terms of revenue, Japan accounted for 4.9% of the global cancer biomarker market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China cancer biomarker market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,987.6 million by 2033.
No credit card required*
Publish Date: May 11, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Biomarker Market Scope
Cancer Biomarker Market segmentation & scope
Cancer Biomarker Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Hologic Inc | View profile | 6,990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | www.hologic.com |
| CanSino Biologics Inc Class H | View profile | 1,494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | www.cansinotech.com |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Abbott | View profile | - | - | - |
Japan Cancer Biomarker Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cancer Biomarker Market Outlook will help companies and investors design strategic landscapes.
Lung Cancer was the largest segment with a revenue share of 24.65% in 2025.
Horizon Databook has segmented the Japan cancer biomarker market based on breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer covering the revenue growth of each sub-segment from 2021 to 2033.
- Japan Cancer Biomarker Market Type Outlook (Revenue, USD Million , 2021-2033)
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Others
- Japan Cancer Biomarker Market Biomolecule Outlook (Revenue, USD Million , 2021-2033)
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Japan Cancer Biomarker Market Application Outlook (Revenue, USD Million , 2021-2033)
- Drug Discovery and Development
- Diagnostics
- Personalized Medicine
- Japan Cancer Biomarker Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Polymerase Chain Reaction (PCR)-based Technologies
- Next-Generation Sequencing (NGS)-based Technologies
- Immunoassay-based Technologies
- In Situ Hybridization (ISH) & Cytogenetic Technologies
- Mass Spectrometry-based Technologies
- Imaging-based Biomarker Technologies
Reasons to subscribe to Cancer Biomarker Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cancer Biomarker Market Outlook databook
- Our clientele includes a mix of Cancer Biomarker Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Cancer Biomarker Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Cancer Biomarker Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Cancer Biomarker Market, 2021-2033 (US$M)
Japan Type - Cancer Biomarker Market Statistics, 2025 - 2033 (US$M)
